Medication info
Lotrovant 20 mg (Rosuvastatin Calcium)

Lotrovant 20 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/Alu-Alu X3)
Approval status
Active

MFDS item code 201400155 · Approved 2014.01.15 · Insurance code 648103350

Summary

Main use
Improves dyslipidemia, inhibits the progression of atherosclerosis, and reduces the risk of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: Dose adjustment is not required. 4. Patients with renal impairment: Dose adjustment is not required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
Child dose
Ages 10 ~ 17 years: The usual dosage range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on administration of doses higher than 20 milligrams in pediatric patients.) Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improves dyslipidemia, inhibits the progression of atherosclerosis, and reduces the risk of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • primary dysbetalipoproteinemia
  • coronary heart disease
  • stroke
  • myocardial infarction
View approved original text

This medication is used as an adjunct when primary hypercholesterolemia and mixed dyslipidemia cannot be controlled by diet and exercise. It is also effective as an adjunct to diet or other lipid-lowering therapy in patients with homozygous familial hypercholesterolemia. It lowers total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis. Furthermore, it helps reduce LDL cholesterol and apo-B protein levels in pediatric patients aged 10 to 17 years with severe hypercholesterolemia. It is used as an adjunct to diet in patients with primary dysbetalipoproteinemia and contributes to reducing the risk of cardiovascular diseases. In particular, it lowers the risk of stroke, myocardial infarction, and arterial revascularization in middle-aged or older patients with high-sensitivity C-reactive protein levels who have risk factors. This medication aims to improve hypercholesterolemia and cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: Dose adjustment is not required. 4. Patients with renal impairment: Dose adjustment is not required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Child dose

Ages 10 ~ 17 years: The usual dosage range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on administration of doses higher than 20 milligrams in pediatric patients.) Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in patients who are allergic to certain components. It should not be administered in the presence of active liver disease or severe hepatic impairment. Patients with muscle disorders or related muscle issues are not suitable for this medication. Patients taking cyclosporine or those with severe renal dysfunction should also avoid this treatment. Pregnant or nursing women should not use this medication, and women of childbearing potential should employ appropriate contraception. Patients at high risk for myopathy or rhabdomyolysis should particularly avoid high-dose administration. This medication contains lactose, so patients with lactose intolerance should be cautious. Patients with a history of hepatic impairment or excessive alcohol consumption should undergo repeated liver function tests before and during treatment. If symptoms of muscle pain or weakness occur, tell your healthcare provider immediately and get tested. Treatment may need to be withheld during severe physical stress or serious illness. There may be interactions with other medications, so any concurrent medications should be disclosed to a healthcare provider. Particular caution is needed when combined with fibrate-class drugs due to the increased risk of muscle-related adverse reactions. This product can occasionally cause serious skin reactions or liver damage, so if rash or jaundice appear, use should be stopped immediately. Clinical trials and post-marketing reported side effects include headache, dizziness, digestive disorders, and myalgia, which are mostly mild and transient. In case of overdose, there is no specific antidote, so treatment should be symptomatic, and liver function and muscle enzyme tests are required. Dizziness may occur when driving or operating machinery, so caution is advised. In Asian individuals, blood concentrations may be higher, so dosage adjustments may be necessary. There is limited evidence of effects on growth and secondary sexual characteristics in children and adolescents, so cautious use is recommended.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to maintain storage temperatures between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/Alu-Alu X3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.